According to a study done by the Fred Hutchison Cancer Cancer, a quick three-question survey as part of patient intake can help women with the symptoms of ovarian cancer be diagnosed with the disease sooner. The survey asks women if they have had abdominal/pelvic pain, feel full quickly when they eat and/or abdominal bloating. Women … Continued
09/25/2012 In a new study of 825 women published in the prestigious journal Nature, members of The Cancer Genome Atlas Network identified four major biological subtypes of breast cancer: luminal A, luminal B, HER2 “enriched,” and basal-like. Basal-like tumors were found to be more like an aggressive form of ovarian cancer, high grade serous ovarian … Continued
09/25/2012 Research published in the Oct. 2012 Journal of Evidence-Based Complementary and Alternative Medicine showed that ovarian cancer survivors who “participated in both regular exercise and yoga had higher scores in physical functioning, fewer limitations with physical and emotional health, less pain, and more vitality than survivors who reported participating in regular exercise only. These … Continued
Recognizing the community’s concern about the USPSTF recommendation regarding screening for ovarian cancer in September 2012, OCRF responded by writing a New York Times Letter to the Editor to reinforce the fact that research is the key and expand our message to a much wider audience. It was published on September 21, 2012.
A study of 240 patients with ovarian cancer concluded that young women with early stage disease be provided the option of fertility sparing surgery, rather than aggressive debulking. The study found that most women with early stage disease who had fertility sparing surgery who tried to get pregnant were successful. Read the abstract here
09/11/2012 Confirming the position taken in draft guidelines released in April, the US Preventive Services Task Force (USPSTF) recommended that women do not routinely get screened for ovarian cancer if they are not at high risk for the disease. The panel found that such screening can put women at increased risk of unnecessary harm, such as … Continued
Washington, DC—On September 10, the United States Preventive Services Task Force (USPSTF) updated its recommendations on ovarian cancer screening. Based on current medical evidence, a committee of experts advised that women at average risk of developing ovarian cancer should not be screened for the disease. The recommendation does not apply to women who are experiencing … Continued
Carey Fitzmaurice first painted her toes teal in 2007 as a way to wear the awareness color at the Ovarian Cancer National Alliance’s Annual Conference. “I didn’t own as much teal clothing then,” Carey recalls. A few weeks later, Carey painted her toes teal again in preparation for National Ovarian Cancer Awareness Month. At the … Continued
Advocate Report: Summer 2012 Susan Leighton Summer 2012 was filled with an abundance of advocacy opportunities including the American Association of Cancer Researchers (AACR) Survivor-Scientist Program, the Drug Information Association (DIA) Fellow Program, OCNA’s National Conference, and the Biennial Cancer Survivorship Research Conference. As I began making the rounds of this year’s events, I truly … Continued
08/23/2012 According to a new study published in Cancer Research, Australian researchers have identified a gene that plays a significant role in the development of high-grade serous ovarian cancer tumors becoming resistant to liposomal doxorubicin (commonly known as Doxil), which is commonly used to treat recurrent ovarian cancer. Investigating the changes in a tumor from … Continued
08/23/2012 Reported online last week in Science Translational Medicine, researchers at MIT and Harvard used nanoparticles to demonstrate the nanoparticles that target a protein called ID4 can reduce ovarian cancer tumors in mice. Researchers hope that this approach could help speed the development of new drugs. As new technology allows researchers to sequence cancer cell … Continued
A study of 637 Japanese women with ovarian, fallopian or primary peritoneal cancer showed that dose dense chemotherapy provided a benefit. The standard of care arm provided chemotherapy every three weeks, the dose dense arm provided one of the drugs every week and the other every three weeks. Women who were on the dose dense … Continued
Get email updates about research news, action alerts, and ways to join the fight.
